background image

1

 

 

Fifth stage 

Gynecology 

Lec-4

 

  اسماء

13/4/2016

 

 

Malignant disease of the body of the uterus

 

 

Uterine cancer: 

  Endometrial cancer may sometimes be referred to as uterine cancer. However, 

different cancers may develop not only from the endometrium itself but also from 
other tissues of the uterus, including cervical cancer, sarcoma of the myometrium, and 
trophoblastic disease. 

  Corpus cancer accounts for 3% of cancer in females. 
  1.Endometrial carcinoma which arise from the lining of the uterus. 
  0r 2.Sarcoma arise from the stroma of endometrium or from myometrium.  
  The incidence is at 60 years & more ,75% of cases usually occur in the post menopausal 

period 

 

Risk factors for Endometrial Cancer: 

  high levels of estrogen  
  endometrial hyperplasia  
  obesity  
  hypertension  
  polycystic ovary syndrome[citation needed]  
  nulliparity (never having carried a pregnancy)  
  infertility (inability to become pregnant)  
  early menarche (onset of menstruation)  
  late menopause (cessation of menstruation)  
  endometrial polyps or other benign growths of the 

uterine lining  

  diabetes  
  Tamoxifen  
  high intake of animal fat[citation needed]  
  pelvic radiation therapy  
  breast cancer  
  ovarian cancer  
  heavy daily alcohol consumption (possibly a risk factor) 

 

 


background image

2

 

 

Factors reduce risk of endometrial carcinoma: 

  oral contraception.  
  progestogens. 
  Smoking. 

 

Pathology

The histopathology of endometrial cancers is highly diverse. The most common finding is a 
well-differentiated endometrioid adenocarcinoma, which is composed of numerous, small, 
crowded glands with varying degrees of nuclear atypia, mitotic activity, and stratification. 
This often appears on a background of endometrial hyperplasia.  

Lymphatic spread occurs later and is less frequent than in cases of cervical carcinoma. 

Remote metastases in lungs, bones or else-where are not common but occur more often 
than with cervical carcinoma 

 

Clinical presentation: 

Symptoms 

1. The classic symptom is bleeding 

A. Post menopausal bleeding in 75-80 %.  

This symptom should be assumed to be caused by carcinoma of endometrium until proved 
otherwise. Women with post menopausal bleeding in women not taking hormone 
replacement therapy has 10% risk of having a genital tract cancer   

B. In premenopausal women may present as:  

            * intermenstrual bleeding 

            *menorrhagia.                      

2. Watery or purulent vaginal discharge (blood stained). 

3. Pain is a late symptom and denotes extensive spread of disease. 

4. Abnormal screening test. 

 

Signs 

A full general and systematic examination is indicated.   

Enlarged lymph nodes in the groin or supraclavicular fossa may be found. 


background image

3

 

 

Breast should be palpated. 

Uterine enlargement can be palpated. 

Pelvic examination: 

Bleeding through cervix. 

Secondary metastasis in vagina, urethra. 

 

Investigations: 

  A Pap smear may be either normal or show abnormal cellular changes.  
  Endometrial curettage is the traditional diagnostic method. Both endometrial and 

endocervical material should be sampled.  

  If endometrial curettage does not yield sufficient diagnostic material, a dilation and 

curettage (D&C) is necessary for diagnosing the cancer.  

  Hysteroscopy allows the direct visualization of the uterine cavity and can be used to 

detect the presence of lesions or tumours. It also permits the doctor to obtain cell 
samples with minimal damage to the endometrial lining (unlike blind D&C).  

  Endometrial biopsy or aspiration may assist the diagnosis.  
  Transvaginal ultrasound to evaluate the endometrial thickness in women with 

postmenopausal bleeding is increasingly being used to evaluate for endometrial 
cancer.  

  An endometrial thickness exceeding 4 to 5 mm on ultrasound is suggestive of 

endometrial pathology in such women.  

  Sonohysterography: 
  It may improve delineation of endometrial polyps.  
  both D&C and Pipelle biopsy curettage give 65-70% positive predictive value. But most 

important of these is hysteroscopy which gives 90-95% positive predictive value. 

 

  

 

 

 

  Recently, a new method of testing has been introduced called the TruTest, offered 

through Gynecor. It uses the small flexible Tao Brush to brush the entire lining of the 
uterus. This method is less painful than a pipelle biopsy and has a larger likelihood of 
procuring enough tissue for testing. Since it is simpler and less invasive, the TruTest can 
be performed as often, and at the same time as, a routine Pap smear, thus allowing for 
early detection and treatment 


background image

4

 

 

  Magnetic resonance imaging (MRI): 
  It is expensive and not practical to screen all women.  
  It used for evaluation of endometrial thickness and to predict myometrial invasion. 

 

Staging of Endometrial Cancer: 

— 

I: Confined to uterine corpus 

◦  IA: limited to endometrium 

◦  IB: invades less than ½ of myometrium 

◦  IC: invades more than ½ of myometrium 

 

 

— 

II: invades cervix but not beyond uterus 

◦  IIA: endocervical gland involvement only 

◦  IIB: cervical stroma involvement 

 

— 

III: local and/or regional spread 

◦  IIIA: invades serosa/adnexa, or positive cytology 

◦  IIIB: vaginal metastasis 

◦  IIIC: metastasis to pelvic or para-aortic lymph nodes 

 

— 

IVA: invades bladder/bowel mucosa 

— 

IVB: distant metastasis 

 

Five Year Survival: 

— 

Stage I: 81-91% 

72% diagnosed at this stage 

— 

Stage II: 71-78% 

— 

Stage III: 52-60% 

— 

Stage IV: 14-17% 

3% diagnosed at this stage 


background image

5

 

 

Spread Patterns: 

  Direct extension  

◦  most common 

  Transtubal  
  Lymphatic 

◦  Pelvic usually first, then para-aortic 

  Hematogenous 

◦  Lung most common 

◦  Liver, brain, bone 

 

Treatment: 

  Stage IB or less: total hyst/BSO/PPALND, cytology 
  Stage IC to IIB: total hyst/BSO/PPALND, cytology, adjuvant pelvic XRT 
  Stage III: total hyst/BSO/PPALND, cytology, adjuvant chemotherapy 
  Stage IV: palliative XRT and chemotherapy 

 

Methods of Endometrial Cancer Treatment: 

  The treatment of endometrial carcinoma is usually: 
     * surgical. 
     * Radiotherapy  
     * Hormone therapy: Progestogens inhibit the rate of growth and spread of 

endometrial carcinoma. 

 

Other Types of Uterine Cancer: 

  Leiomyosarcoma 

o  Rapidly growing fibroid should be evaluated  

  Stromal sarcoma 
  Carcinosarcoma (MMMT) 

 

Uterine Sarcomas: 

  Account for fewer than 10% of all corpus cancers. 
  Types: 


background image

6

 

 

  ( Carcinosarcoma, leiomyosarcoma, Endometrial stromal sarcoma, adenosarcoma) 
  Exposure to radiation may enhance the development of pelvic sarcomas  
  Abnormal vaginal bleeding most frequent presenting symptom for all histologic types. 
  No specific staging system (commonly use staging of endometrial carcinoma) 
  Management of Uterine Sarcomas: 
  Surgery is the hallmark of treatment with total abdominal hysterectomy and bilateral 

salpingo-oopherectomy (TAH/BSO) being the standard procedure. 

 




رفعت المحاضرة من قبل: Abdalmalik Abdullateef
المشاهدات: لقد قام 7 أعضاء و 143 زائراً بقراءة هذه المحاضرة








تسجيل دخول

أو
عبر الحساب الاعتيادي
الرجاء كتابة البريد الالكتروني بشكل صحيح
الرجاء كتابة كلمة المرور
لست عضواً في موقع محاضراتي؟
اضغط هنا للتسجيل